Voyager Therapeutics, Inc. (VYGR): R&D Expense
$134.67M
Year ended 2025-12-31
$118.46M
Trailing 12 months to 2026-06-30
+30.4%
3-year compound annual growth
+4.4%
5-year compound annual growth
+17.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $134.67M | +5.7% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $127.37M | +38.2% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $92.17M | +51.7% | 2026-03-09, From 2023-01-01 |
| 2022-12-31 | $60.76M | -17.6% | 2025-03-11, From 2022-01-01 |
| 2021-12-31 | $73.79M | -32.2% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $108.75M | -9.2% | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | $119.73M | +84.5% | 2022-03-08, From 2019-01-01 |
| 2018-12-31 | $64.91M | +4.2% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $62.26M | +47.4% | 2020-03-03, From 2017-01-01 |
| 2016-12-31 | $42.25M | +52.6% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $27.68M | +211.1% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $8.90M | n/a | 2017-03-15, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $134.67M | +5.7% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $89.95M | -54.9% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $112.67M | +1.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $316.57M | +31.8% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $250.0K | -18.6% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $104.24M | -5.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $72.72M | -10.9% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $54.17M | -9.0% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $19.57M | +50.9% |
Compare VYGR, EDIT, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗